promannkind, I just checked, and Spiro went below 120 in just two days on Afrezza. 19 days later he got into the 80s. You can get samples and a first prescription free flyer plus next prescription $30. Rather than take any orals, I would pay for Afrezza myself if/until the insurance comes through. Since you are plagued by the after meal spikes, it should be easy with Afrezza to show your doc fast improvement in range and the start of a much lower A1c. Then if special things are needed for insurance, the doc can be more motivated to help.
promannkind, sounds like you are a type 2. You really need to read up on side effects of metformin as well as Januvia. I would never take either of those drugs, and I mean I would refuse. Either and both can cause plenty of trouble for you. I have no idea what your A1c is now, but if it is not way high, you likely would just need Afrezza at meal times and check how you do after a month or two on your blood glucose levels. If your A1c is way high and you are type 2, you will likely need subcutaneous insulin anyway in addition to Afrezza.
bigkid531, About an hour ago I did exactly what you suggested, i.e., I read the SeekingAlpha (SA) transcript of the SNY earnings call. It appears the transcript could not provide an answer to my question either, because it simply states "unknown" for the word I am trying to discover relative to Germany. Perhaps you have not read the transcript you cited.
In addition I have found Tremendous transcription errors in SA transcript documents when I have from time to time compared certain segments of an audio call (that mattered to me) to the text of any particular transcript. The quality of the SA transcripts is less than customer delightful, but it is essentially free. There is that. I should also say from time to time I have found text in SA transcripts that is correct when compared to my misunderstanding of words in an audio call. Free is good.
mnholdem, so it would appear to make a reasonable comparison you would need to find the Insulin Analogs, Short-Acting group numbers. Then it might be more of an apples to apples comparison of the numbers.
kimi_held, I listened to the Sanofi earnings call replay, and toward the end of the call they talked about an ADNOC procedure some drug (I think it was Toujeo) did not have to go through in Germany. I cannot be sure how to spell adnoc, because it was hard for me to understand the term through their French accents. Do you recognize this term that drugs sometimes go through in Germany? Is it similar to an advisory committee with the FDA in the USA?
sellhighdrinklow, If I had a cardiologist who prescribed Crestor, refused to prescribe Lipitor, but I wanted Lipitor, I would go to another cardiologist who would give me a Lipitor prescription. What is the issue with diabetics not mostly doing the same thing if their endo/gp will not prescribe(not just sampes) Afrezza when patients say they want it?
Why did you get just Afrezza samples and not a prescription for Afrezza? While you are feeling better, it appears your Dexcom is indicating you must be in some blood glucose range you have not experienced before.
I read your posts about the hassle (what I call hassle anyway) you had to go through just to get the doc to agree to give you samples.
amstelytle, I noticed that too, because the Sanofi table and text stated explicitly the Toujeo, "Sales of the product were #$%$7 million in the first quarter which primarily reflected wholesaler demand in advance of the launch." However the Afrezza statement was, "Sales of the product were #$%$1 million in the first quarter."
It seemed to me there was a difference the earnings press release was noting for the reader. The quoted text above is directly from the Sanofi earnings press release.
amstelytle, the first 90 day doctor-measured A1c's will start in May, and then four and five month duration A1c's can follow after that when all the other prandial insulins are for certain out of the system. The real, much reduced, doctor-measured A1c's will get plenty of doctors' attention coming from so many differing types of diabetics with so many differing eating habits, etc.
factspls88, I read Brian Feroldi's article you referenced. He recognizes in the article MNKD has a good drug pipeline possible with the Technosphere delivery system. He lives in either Rhode Island or the Boston area, and perhaps he went to the Andrea Leone-Bay presentation on inhaled oxyntomodulin yesterday. He just recently was a territory manager for Insulet, and that means he knows plenty about insulin and diabetes. He just started writing articles this month after a good number of years with Insulet.
Has anyone seen an analyst's report on Leone-Bay's presentation today in Boston on inhaled oxyntomodulin. It is positioned as a possible treatment for obesity. Perhaps someone reading this may have been at the event today.
joeblow180, OK I found you answered a few hours ago you took two 4U doses of Afrezza back to back. Thanks for the information.
doctorgreenback, just a point of order. I believe you meant to write, "they are NOT worried about 4-12u." Am I wrong?
doctorgreenback, why is there talk about a 30U dose. Isn't that an extreme outlier type 2. If yes, why is that an important concern?
dtrouble1003, isn't your girlfriend(gf) one who has been to her doctor, and he would not prescribe it to her? I think I remember this some months ago. Is she going to watch and love it from social media without getting in the fight to use Afrezza?
She will present at 11 am. Dry Powder Formulations for the Inhalation of Oxyntomodulin presentation. The audience will learn about oxyntomodulin, a potential new obesity therapy and about the administration of peptides by oral inhalation using a simple, patient-friendly approach.
Obesity is a rapidly becoming a global epidemic and underlies many disease conditions including diabetes and cardiovascular disease. Current treatment options are limited and are challenged by undesirable side effects. Oxyntomodulin (OXY) is an endogenous peptide hormone that signals satiety in healthy individuals. High circulating OXY concentrations are associated with satiety and low OXY concentrations are associated with a feeling of hunger. This activity profile positions OXY as a potential treatment for obesity. To address this unmet medical need, this presentation will introduce an approach to developing an orally inhaled dry powder OXY product administered using a small, breath-powered inhaler for obesity therapy.
This is just a reminder.
jsuesssoprano, I took a look at the greater than 2000 jan 2016 3.50 calls as you indicated. Just as adisa_kl and I discussed a week ago, these long dated, in the money calls were traded for essentially no time premium -- although the calls are 9 months away from expiration. I still would like to hear from adisa_kl and anyone else who would be offering this volume of calls for no time premium.
joeblow180, I think my reading comprehension is good. Novolog/Humalog are rapid acting insulins (RAA), and you are not using them in any way(as I wrote above), including in your pump. I assume you pump something like Levemir or Humulin, which are long acting insulins.
seyhey44, check your 6th sentence beginning with, "We also know afrezza...." I think you have a typographical error in your sentence.
mnholdem, no matter what Sanofi says the attributes of Toujeo are, such as, one injection per day, Sanofi is offering it at a premium price to all the basal insulins on the market. With Lantus going generic and such a large number of Lantus users, Toujeo will have a rough time with lower priced generic Lantus plus all the other basal insulins out there. I do not yet see an overpowering reason insurance companies would pay premium prices for Toujeo when lower price generic Lantus is available.